Inhibitory effect of thrombin on the expression of secretory group IIA phospholipase A 2

Journal of Cellular Biochemistry

Volumn 112, Issue 9, 2011, Pages 2502-2507

  Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

Author keywords

HUVEC; Lipid raft; PAR 1; sPLA 2 IIA; Thrombin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ESTERASE; LIPOPOLYSACCHARIDE; METHYL BETA CYCLODEXTRIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2 GROUP IIA; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTICHOLESTEREMIC AGENTS; BETA-CYCLODEXTRINS; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION; GROUP II PHOSPHOLIPASES A2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOPOLYSACCHARIDES; OLIGOPEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; THROMBIN;

EID: 84860408586     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23172     Document Type: Article

References (44)

1. Alaoui-El-Azher M, Wu Y, Havet N, Israel A, Lilienbaum A, Touqui L,. 2002. Arachidonic acid differentially affects basal and lipopolysaccharide- induced sPLA(2)-IIA expression in alveolar macrophages through NF-kappaB and PPAR-gamma-dependent pathways. Mol Pharmacol 61: 786-794. (Pubitemid 34273158)
2. Bae JS, Rezaie AR,. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 100: 101-109. (Pubitemid 351948751)
3. Bae JS, Rezaie AR,. 2009. Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Thromb Haemost 101: 513-520.
4. Bae JS, Rezaie AR,. 2010. Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms. Thromb Res 125: e9-e15.
5. Bae JS, Yang L, Manithody C, Rezaie AR,. 2007a. Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J Biol Chem 282: 9251-9259. (Pubitemid 47093484)
6. Bae JS, Yang L, Manithody C, Rezaie AR,. 2007b. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110: 3909-3916. (Pubitemid 350248446)
7. Bae JS, Yang L, Rezaie AR,. 2007c. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 104: 2867-2872. (Pubitemid 46327971)
8. Bae JS, Kim YU, Park MK, Rezaie AR,. 2009. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 kinase. J Cell Physiol 219: 744-751.
9. Balsinde J, Balboa MA, Insel PA, Dennis EA,. 1999. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 39: 175-189.
10. Beck G, Yard BA, Schulte J, Haak M, van Ackern K, van der Woude FJ, Kaszkin M,. 2003. Secreted phospholipases A2 induce the expression of chemokines in microvascular endothelium. Biochem Biophys Res Commun 300: 731-737. (Pubitemid 36268898)
11. Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD,. 2005. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 32: 417-423. (Pubitemid 40381410)
12. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR,. 1996. Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 183: 821-827.
13. Coughlin SR,. 2000. Thrombin signalling and protease-activated receptors. Nature 407: 258-264.
14. Coughlin SR,. 2001. Protease-activated receptors in vascular biology. Thromb Haemost 86: 298-307. (Pubitemid 32663960)
15. Coughlin SR,. 2005. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3: 1800-1814. (Pubitemid 41716567)
16. Crowl RM, Stoller TJ, Conroy RR, Stoner CR,. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 266: 2647-2651. (Pubitemid 21909111)
17. Dennis EA,. 1997. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci 22: 1-2. (Pubitemid 27056087)
18. Feistritzer C, Riewald M,. 2005. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105: 3178-3184.
19. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG,. 2005. Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280: 17286-17293. (Pubitemid 41389197)
20. Flynn JT, Hoff H III., 1995. Lipopolysaccharide induces time-dependent increases in prostaglandin H synthase-2 and cytosolic phospholipase A2 mRNA in cultured human microvessel-derived endothelial cells. Shock 4: 433-440.
21. Grass DS, Felkner RH, Chiang MY, Wallace RE, Nevalainen TJ, Bennett CF, Swanson ME,. 1996. Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J Clin Invest 97: 2233-2241. (Pubitemid 26165712)
22. Joyce DE, Grinnell BW,. 2002. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 30: S288-S293. (Pubitemid 34508005)
23. Joyce DE, Chen Y, Erger RA, Koretzky GA, Lentz SR,. 1997. Functional interactions between the thrombin receptor and the T-cell antigen receptor in human T-cell lines. Blood 90: 1893-1901. (Pubitemid 27377299)
24. Komarova YA, Mehta D, Malik AB,. 2007. Dual regulation of endothelial junctional permeability. Sci STKE 2007: re8.
25. Kudo I, Murakami M,. 2002. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 68-69: 3-58.
26. Kuwata H, Fujimoto C, Yoda E, Shimbara S, Nakatani Y, Hara S, Murakami M, Kudo I,. 2007. A novel role of group VIB calcium-independent phospholipase A2 (iPLA2gamma) in the inducible expression of group IIA secretory PLA2 in rat fibroblastic cells. J Biol Chem 282: 20124-20132. (Pubitemid 47100034)
27. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA,. 2001. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7: 1291-1297. (Pubitemid 34007932)
28. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R,. 2001. Proteinase-activated receptors. Pharmacol Rev 53: 245-282. (Pubitemid 32476117)
29. Menschikowski M, Hagelgans A, Heyne B, Hempel U, Neumeister V, Goez P, Jaross W, Siegert G,. 2005. Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochim Biophys Acta 1733: 157-171. (Pubitemid 40603659)
30. Menschikowski M, Hagelgans A, Siegert G,. 2006. Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat 79: 1-33.
31. Mosnier LO, Zlokovic BV, Griffin JH,. 2007. The cytoprotective protein C pathway. Blood 109: 3161-3172. (Pubitemid 46572500)
32. Mounier CM, Hackeng TM, Schaeffer F, Faure G, Bon C, Griffin JH,. 1998. Inhibition of prothrombinase by human secretory phospholipase A2 involves binding to factor Xa. J Biol Chem 273: 23764-23772. (Pubitemid 28435709)
33. Murakami M, Shimbara S, Kambe T, Kuwata H, Winstead MV, Tischfield JA, Kudo I,. 1998. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem 273: 14411-14423. (Pubitemid 28319161)
34. Nakano T, Ohara O, Teraoka H, Arita H,. 1990. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem 265: 12745-12748.
35. Oka S, Arita H,. 1991. Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression. J Biol Chem 266: 9956-9960. (Pubitemid 21906748)
36. Ossovskaya VS, Bunnett NW, de Garavilla L, Vergnolle N, Young SH, Ennes H, Steinhoff M, D'Andrea MR, Mayer EA, Wallace JL, Hollenberg MD, Andrade-Gordon P,. 2004. Protease-activated receptors: Contribution to physiology and disease. Physiol Rev 84: 579-621. (Pubitemid 38365493)
37. Pruzanski W, Vadas P,. 1991. Phospholipase A2-A mediator between proximal and distal effectors of inflammation. Immunol Today 12: 143-146.
38. Shankar R, de la Motte CA, Poptic EJ, DiCorleto PE,. 1994. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem 269: 13936-13941.
39. Six DA, Dennis EA,. 2000. The expanding superfamily of phospholipase A(2) enzymes: Classification and characterization. Biochim Biophys Acta 1488: 1-19.
40. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD,. 2005. Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26: 1-43. (Pubitemid 40209385)
41. Tanaka K, Kato T, Matsumoto K, Yoshida T,. 1993. Antiinflammatory action of thielocin A1 beta, a group II phospholipase A2 specific inhibitor, in rat carrageenan-induced pleurisy. Inflammation 17: 107-119. (Pubitemid 23105185)
42. Vadas P, Pruzanski W, Kim J, Fornasier V,. 1989. The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2. Am J Pathol 134: 807-811. (Pubitemid 19111247)
43. Waydhas C, Nast-Kolb D, Duswald KH, Lehnert P, Schweiberer L,. 1989. Prognostic value of serum phospholipase A in the multitraumatized patient. Klin Wochenschr 67: 203-206. (Pubitemid 19056182)
44. Zeiher BG, Steingrub J, Laterre PF, Dmitrienko A, Fukiishi Y, Abraham E,. 2005. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 33: 1741-1748. (Pubitemid 41153699)